Free shipping on all orders over $ 500

Ociperlimab

Cat. No. M25084
Ociperlimab Structure
Synonym:

BGB-A1217

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer.

Chemical Information
CAS Number 2342597-93-5
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Lin Zhang, et al. Cancer Control. Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody

[2] Xin Chen, et al. Front Immunol. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models

Related TIGIT Products
Dargistotug

Dargistotug is a fully human IgG1 monoclonal antibody targeting T-cell immunoglobulin and the ITIM structural domain (TIGIT) that induces an immune response targeting cancer cells by blocking the TIGIT pathway.

Tamgiblimab

Tamgiblimab (IBI939) is a fully human monoclonal antibody targeting T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT). Tamgiblimab has anticancer effects.

Domvanalimab

Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used in research of cancer.

Vibostolimab

Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research.

Tiragolumab

Tiragolumab is an immune checkpoint inhibitor that binds to T-cell immunoglobulin and the structural domain of ITIM (TIGIT), targets TIGIT and has an intact Fc region. Tiragolumab is indicated for use in studies related to solid tumors.

  Catalog
Abmole Inhibitor Catalog




Keywords: Ociperlimab, BGB-A1217 supplier, TIGIT, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.